- Indication
- Growth disturbance caused by growth hormone deficiency in children
- RAG rating
- Red
- Document type
- Decision document
- Place
- Hertfordshire and West Essex ICB
- Output type
- Pharmacy / Prescribing
Somapacitan
Somapacitan (Sogroya)
HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)
Somapacitan for treating growth hormone deficiency in people 3 to 17 years
RED
Recommended for restricted prescribing by specialist only.
Not recommended for primary care prescribing.
Name generic (trade) Somapacitan (Sogroya®)
What it is Recombinant human growth hormone
Indication Recommended for the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.
Date decision last revised June 2025
Decision status Final
NICE / SMC Guidance NICE TA 1066 recommended for restricted use, SMC accepted for restricted use
HWE APC recommendation:
Somapacitan is recommended, within its marketing authorisation, as an option for treating growth disturbance in children and young people aged 3 years and over in line with the recommendations in NICE TA 1066.
Somapacitan treatment should be reviewed in line with discontinuation criteria already agreed across HWE ICB for somatropin/somatrogon treatment:
Poor response: growth velocity in the first year of treatment <50% above baseline value
Growth velocity is less than <2cm total growth in 1 year
Final height is attained. Confirmation of final height: bone age is >14yrs (girls) or >16yrs (boys)
Insurmountable problems with adherence
National tariff excluded.
If somapacitan is considered one of a number of suitable treatments (including any preparation of somatropin), the least expensive (taking into account administration costs, dosage, price per dose and commercial arrangements) should be chosen.
RED STATUS:
NOT RECOMMENDED FOR PRIMARY CARE PRESCRIBING.
RECOMMENDED FOR RESTRICTED PRESCRIBING BY SPECIALISTS
NICE TA 1066 recommendations:
Somapacitan can be used, within its marketing authorisation, as an option to treat growth failure caused by growth hormone deficiency in people 3 to 17 years. Somapacitan can be used if the company provides it at the same price or lower than that agreed with the Medicines Procurement and Supply Chain, where applicable.
Use the least expensive option of the available treatments (including somapacitan and any preparation of somatropin). Take account of administration costs, dosages, price per dose and commercial arrangements. If the least expensive option is unsuitable, people with the condition and their healthcare professional should discuss the advantages and disadvantages of other treatments.